Table 1 Clinicopathologic characteristics and prognosis in NSCLC lymphatic metastasis
From: Advances in lymphatic metastasis of non-small cell lung cancer
Makers | Tumor simple size | Function | Related molecules and pathways | Clinicopathologic characteristics | Prognosis | Ref. |
|---|---|---|---|---|---|---|
ANGPTL2 | 233 | Accelerator | VEGF-A | More LNM and advanced TNM stage | Poorer OS | [62] |
ANGPTL2 | 81 | Accelerator | NF-ĸB | More TAM infiltration and larger tumor size | Poorer OS | [64] |
Ang-2 | 575 | Accelerator | - | More LNM and advanced tumor stage | Poorer OS | [65] |
PDGF-B | 109 | Accelerator | PDGFR-β/ VEGF-C | More LNM, larger tumor size, and worse histological differentiation | Poorer OS | [68] |
PDGF-A PDGF-B | 335 | Accelerator | VEGFR- 3 | More LNM | Poorer DSS | [69] |
PDGF-B | 127 | Accelerator | PDGFR-β | More LNM, LMVD, advanced TNM stage and higher PLT counts | - | [70] |
Platelet | 852 | Accelerator | VEGF-C | More LNM | - | [71] |
Platelet | 883 | Accelerator | - | More LNM and advanced TNM stage | Poorer OS | [72] |
HGF-α | 113 | Accelerator | c-Met/VEGF-C | More LNM and LMVD | Poorer OS | [73] |
IGFBP7 | 97 | Accelerator | - | More LNM and ptLVD | - | [74] |
FGF2 | 335 | Accelerator | VEGFR-3 | Higher performance status, advanced pathologic T-stage, N-stage, worse histologic differentiation, and more vascular infiltration | Poorer DSS | [75] |
Shh signal pathway | 40 | Accelerator | LYVE-1 | Worse histology and more severe visceral pleural invasion | Poorer OS | [76] |
STAT3 | 50 | Accelerator | - | More LN micrometastasis | - | [77] |
SCC-S2 | 25 | Accelerator | - | More LNM, TNM, and ki-67 expression | Poorer OS | [78] |
SCP3 | 89 | Accelerator | VEGF-C VEGF-D | - | Poorer OS | [79] |
EV-packaged circTLCD4-RWDD3 | 312 | Accelerator | PROX1 | More LNM and MLVD | Poorer OS and DFS | [83] |
MiR-128 | 30 | Inhibitor | VEGF-C/ VEGFR-3/ERK/AKT/p38 | Less LNM, lower pathological stage, and better differentiation | - | [85] |
MiR-22 | 49 | Inhibitor | VEGFR-3 | Less LNM, MLVD, lower TNM stage, smaller tumor size, and less vascular invasion | - | [86] |
CCR7 | 90 | Accelerator | VEGF-D | More LNM, LVD, and advanced TNM stage | Poorer OS | [49] |
IL-7/IL-7R | 100 | Accelerator | VEGF-D | More LNM, LVD, and advanced TNM stage | Poorer OS | [92] |
IL-17 | 52 | Accelerator | LYVE-1+ | More LVD and advanced TNM stage | Poorer OS and DFS | [94] |
IL-17 | 36 | Accelerator | VEGF-C | More LNM, LVD, and advanced tumor grade | - | [93] |
COX-2 | 65 | Accelerator | VEGF-C | More LNM and LMVD | - | [97] |
Romo1 | 30 | Accelerator | ROS/VEGF-C | - | Poorer OS and DFS | [98] |
CD147 | 46 | Inhibitor | TGF-β/CD147 methylation | Less LNM, TNM, and smaller tumor size | - | [119] |
KAI1 | 312 | Inhibitor | β-catenin/EMT | Less LNM, LVD, and MVD | Better OS and DSS | [121] |
MiR-148a | 48 | Inhibitor | DNMT1/E-Cadherin/ | Less LNM and lower clinical stage | Better OS and DFS | [122] |
SNAI2 TWIST1 | 160 | Accelerator | EMT | - | Poorer OS and RFS | [125] |
JAM-C | 140 | Accelerator | ERK/VEGF-C | More LNM and faster tumor growth | Poorer OS and RFS | [48] |
p-S6 | 350 | Accelerator | - | More LNM and worse histological type | Poorer OS | [127] |